ALXN stock is up 6% since Alexion Pharmaceuticals (NASDAQ:ALXN) announced its third-quarter results on Wednesday, which saw a 23% year-over-year rise in revenue to $1.26 billion USD.
ALXN Stock Outperforming IndustryAlexion reported Q3 earnings of $2.79 per share, which is a 38% increase from $2.02 in the same period last year and also beat the Zacks Consensus Estimate of $2.49. Moreover, revenues of $1.26 billion USD in the quarter also surpassed the Zacks Consensus Estimate of $1.24 billion USD. Revenues were driven by increased sales of Soliris, which brought in $990.5 million USD in sales ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.